Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Adenocarcinoma 1Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × spartalizumab × 1 year × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡